T2 Biosystems Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de T2 Biosystems de 8.4% y 36.3% respectivamente, mientras que el BPA crecerá en un 70.4% al año.

Información clave

8.4%

Tasa de crecimiento de los beneficios

70.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.1%
Tasa de crecimiento de los ingresos	36.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	29 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

T2 Biosystems Q2 2022 Earnings Preview

Aug 12

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

Jul 06

A Roadmap To T2 Biosystems Story

Mar 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:TTOO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	33	-41	-32	N/A	1
12/31/2025	23	-41	-32	N/A	1
12/31/2024	11	-40	-34	N/A	1
12/31/2023	7	-50	-48	-48	N/A
9/30/2023	11	-50	-49	-49	N/A
6/30/2023	13	-52	-52	-52	N/A
3/31/2023	17	-64	-50	-49	N/A
12/31/2022	22	-62	-51	-51	N/A
9/30/2022	24	-64	-51	-50	N/A
6/30/2022	28	-61	-44	-44	N/A
3/31/2022	28	-55	-45	-45	N/A
12/31/2021	28	-49	-39	-39	N/A
9/30/2021	29	-47	-38	-38	N/A
6/30/2021	27	-44	-35	-34	N/A
3/31/2021	23	-43	-38	-37	N/A
12/31/2020	18	-47	-44	-43	N/A
9/30/2020	13	-51	-45	-45	N/A
6/30/2020	10	-54	-52	-52	N/A
3/31/2020	9	-59	-48	-47	N/A
12/31/2019	8	-59	-46	-45	N/A
9/30/2019	7	-60	-45	-45	N/A
6/30/2019	8	-57	-42	-41	N/A
3/31/2019	10	-53	-42	-41	N/A
12/31/2018	11	-51	-41	-40	N/A
9/30/2018	10	-54	-42	-42	N/A
6/30/2018	9	-58	-44	-43	N/A
3/31/2018	6	-61	-48	-47	N/A
12/31/2017	5	-62	-50	-48	N/A
9/30/2017	4	-59	N/A	-47	N/A
6/30/2017	4	-57	N/A	-47	N/A
3/31/2017	4	-56	N/A	-47	N/A
12/31/2016	4	-55	N/A	-46	N/A
9/30/2016	4	-52	N/A	-45	N/A
6/30/2016	4	-51	N/A	-45	N/A
3/31/2016	4	-48	N/A	-42	N/A
12/31/2015	3	-45	N/A	-37	N/A
9/30/2015	2	-42	N/A	-37	N/A
6/30/2015	1	-40	N/A	-33	N/A
3/31/2015	0	-38	N/A	-30	N/A
12/31/2014	0	-36	N/A	-28	N/A
9/30/2014	0	-35	N/A	-24	N/A
6/30/2014	0	-33	N/A	-22	N/A
3/31/2014	0	-31	N/A	-20	N/A
12/31/2013	0	-28	N/A	-18	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TTOO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que TTOO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que TTOO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (36.3% al año) de TTOO crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (36.3% al año) de TTOO crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TTOO se prevé que sea elevada dentro de 3 años.

T2 Biosystems Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 21%, EPS upgraded

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

Consensus revenue estimates decrease by 50%, EPS upgraded

Consensus EPS estimates fall by 15%

Recent updates

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems' Survival Riddle

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

T2 Biosystems, Inc. announced delayed 10-Q filing

T2 Biosystems Q2 2022 Earnings Preview

T2 Biosystems, Inc to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

T2 Biosystems, Inc. to Report Q2, 2022 Results on Aug 15, 2022

T2 Biosystems Receives Non-Compliance Notice from Nasdaq

T2 Biosystems, Inc. Receives Food and Drug Administration Breakthrough Device Designation for the T2Lyme Panel

Consensus forecasts updated

T2 Biosystems, Inc. Provides Preliminary Unaudited Revenue Guidance for the Quarter Ended June 30, 2022 and Provides Revenue Guidance for the Full Year 2022

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule

High number of new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 14%

T2 Biosystems Announces Receipt of Nasdaq Delisting Notice

High number of new directors

T2 Biosystems, Inc. Submits Application with U.S. Food and Drug Administration for Breakthrough Device Designation for T2Biothreat Panel